Current and future therapies for advanced pancreatic cancer

Journal of Surgical Oncology

Volumn 116, Issue 1, 2017, Pages 25-34

  Gupta, Rohan ^a   Amanam, Idoroenyi ^a   Chung, Vincent ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

cytotoxic chemotherapy; pancreas cancer; vaccine therapy

Indexed keywords

CANCER VACCINE; TUMOR MARKER; CA 19-9 ANTIGEN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER RISK; CANCER STAGING; CANCER THERAPY; CLINICAL FEATURE; HUMAN; LOCALLY ADVANCED PANCREATIC CANCER; NEOADJUVANT THERAPY; PANCREAS CANCER; PANCREAS RESECTION; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY PERIOD; REVIEW; RISK FACTOR; ADJUVANT CHEMOTHERAPY; CANCER PAIN; CLINICAL TRIAL (TOPIC); GENETIC PREDISPOSITION; MORTALITY; PANCREAS TUMOR;

BIOMARKERS, TUMOR; CA-19-9 ANTIGEN; CANCER PAIN; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RISK FACTORS;

EID: 85020288182     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24623     Document Type: Review

References (78)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016; 66:7–30.
2. Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015; 148:556–564.
3. Salo-Mullen EE, O'reilly EM, Kelsen DP, et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer. 2015; 121:4382–4388.
4. Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 1987; 316:1511–1514.
5. Vasen H, Gruis N, Frants R, van Der Velden P, Hille E, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000; 87:809–811.
6. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012; 2:41–46.
7. Brentnall TA. Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol. 2005; 6:437–445.
8. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004; 64:2634–2638.
9. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006; 20:197–209.
10. Society AC. American Cancer Society: Cancer Facts and Figures 2016. Atlanta, GA: American Cancer Society; 2016.
11. Bosetti C, Lucenteforte E, Silverman D, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012; 23:1880–1888.
12. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993; 328:1433–1437.
13. Batabyal P, Vander Hoorn S, Christophi C, Nikfarjam M. Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies. Ann Surg Oncol. 2014; 21:2453–2462.
14. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA. 2001; 286:921–929.
15. Xiao M, Wang Y, Gao Y. Association between Helicobacter pylori infection and pancreatic cancer development: a meta-analysis. PLoS ONE. 2013; 8:e75559.
16. Hassan MM, Li D, El-Deeb AS, et al. Association between hepatitis B virus and pancreatic cancer. J Clin Oncol. 2008; 26:4557–4562.
17. Tanaka M. Controversies in the management of pancreatic IPMN. Nat Rev Gastroenterol Hepatol. 2011; 8:56–60.
18. Klimstra DS, Pitman MB, Hruban RH. An algorithmic approach to the diagnosis of pancreatic neoplasms. Arch Pathol Lab Med. 2009; 133:454–464.
19. Kozuka S, Sassa R, Taki T, et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer. 1979; 43:1418–1428.
20. Porta M, Fabregat X, Malats N, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumor site and stage. Clin Transl Oncol 2005; 7:189–197.
21. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 2004; 5:655–663.
22. Ostlere L, Branfoot A, Staughton R. Cicatricial pemphigoid and carcinoma of the pancreas. Clin Exp Dermatol. 1992; 17:67–68.
23. Tummala P, Junaidi O, Agarwal B. Imaging of pancreatic cancer: an overview. J Gastrointest Oncol. 2011; 2:168–174.
24. Warshaw AL, Castillo CF-D. Pancreatic carcinoma. N Engl J Med. 1992; 326:455–465.
25. del Castillo CF, Warshaw L. Peritoneal metastases in pancreatic carcinoma. Hepato-gastroenterology. 1993; 40:430–432.
26. Karachristos A, Scarmeas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg. 2005; 9:1286–1292.
27. Ghaneh P, Wong WL, Titman A, et al. PET-PANC: multi-centre prospective diagnostic accuracy and clinical value study of PET/CT in the diagnosis and management of pancreatic cancer. Pancreatology. 2016; 16:S91.
28. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989; 110:704–709.
29. Ćwik G, Wallner G, Skoczylas T, Ciechański A, Zinkiewicz K. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg. 2006; 141:968–973.
30. Van den Bosch R, Van Eijck C, Mulder P, Jeekel J. Serum CA19-9 determination in the management of pancreatic cancer. Hepato-gastroenterology. 1995; 43:710–713.
31. CONIO M. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer. 1988; 61:2100–2108.
32. Malesci A, Tommasini MA, Bonato C, et al. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology. 1987; 92:60–67.
33. Lamerz R. Role of tumor markers, cytogenetics. Ann Oncol. 1999; 10:S145–S149.
34. Koopmann J, Rosenzweig CNW, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA 19-9. Clin Cancer Res. 2006; 12:442–446.
35. Edge SB, Compton CC, Byrd DR, et al. eds. Pancreas cancer staging. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. NY, USA: Springer; 2010; 7:241–249.
36. Manual AS, Edge SB, Byrd DR, et al. NY, USA: Springer; 2010; 7:241–249.
37. Fong Y, Gonen M, Rubin D, Radzyner M, Brennan MF. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg. 2005; 242:540–547.
38. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362:1605–1617.
39. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014; 371:1039–1049.
40. Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009; 16:1736–1744.
41. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006; 244:10–15.
42. Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013; 63:318–348.
43. Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009; 16:1751–1756.
44. Castellanos JA, Merchant NB. Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol. 2014; 21:747–751.
45. Wiebe LA, Von Roenn JH. Optimizing palliative care of patients with advanced pancreatic cancer, 2009, 28–33.
46. Wiebe LA. A myriad of symptoms: new approaches to optimizing palliative care of patients with advanced pancreatic cancer. Am Soc Clin Oncol Educ Book. 2012; 32:243–248.
47. Wyse JM, Carone M, Paquin SC, Usatii M, Sahai AV. Randomized, double-blind, controlled trial of early endoscopic ultrasound—guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol. 2011; 29:3541–3546.
48. Domínguez-Muñoz JE. Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol. 2011; 26:12–16.
49. Halloran CM, Cox TF, Chauhan S, et al. Partial pancreatic resection for pancreatic malignancy is associated with sustained pancreatic exocrine failure and reduced quality of life: a prospective study. Pancreatology. 2011; 11:535–545.
50. Bond-Smith G, Banga N, Hammond TM, Imber CJ. Pancreatic adenocarcinoma. BMJ. 2012; 344:e2476.
51. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13:1035–1046.
52. Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011; 150:466–473.
53. Petrelli F, Coinu A, Borgonovo K, et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas. 2015; 44:515–521.
54. Hammel P, Huguet F, van Laethem J-L, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016; 315:1844–1853.
55. Katz MH, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009; 16:836–847.
56. Neoptolemos J, Dunn J, Stocken D, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358:1576–1585.
57. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350:1200–1210.
58. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297:267–277.
59. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310:1473–1481.
60. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017; 389:1011–1024.
61. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008; 299:1019–1026.
62. Neoptolemos J, Palmer D, Ghaneh P, et al. ESPAC-4: a multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Pancreatology. 2016; 16:S63.
63. Burris HR, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403–2413.
64. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25:1960–1966.
65. da Cunha Santos G, Dhani N, Tu D, et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer. 2010; 116:5599–5607.
66. Van Cutsem E, Nowara E, Ciuleanu T, et al. Dose escalation to rash for erlotinib plus gemcitabine in patients with metastatic pancreatic cancer: the phase II Rachel (BO21128) study. Br J Cancer. 2014; 111:2067–2075.
67. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364:1817–1825.
68. Von Hoff DD, Ervin TJ, Arena FP, et al. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. Am Soc Clin Oncol. 2013; 369:1691–1703.
69. Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014; 32:2423–2429.
70. Wang-Gillam A, Li C-P, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016; 387:545–557.
71. Gill S, Ko Y-J, Cripps C, et al. PANCREOX: a randomized phase III study of Fluorouracil/Leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016; 34:3914–3920.
72. Chung V, McDonough S, Philip PA, et al. Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: sWOG S1115 study randomized clinical trial. JAMA Oncol. 2016.
73. Diaz L, Uram J, Wang H, et al. Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology. J Clin Oncol. 2016; 34:3003.
74. Overman MJ, Lopez CD, Benson AB, et al. A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC). In ASCO Annual Meeting Proceedings. 2016.
75. Le DT, Wang-Gillam A, Picozzi V, et al. A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: updated results. J Clin Oncol. 2014; 32:177.
76. Le DT, Wang-Gillam A, Picozzi VJ, et al. A phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). J Clin Oncol. 2015; 33:TPS489–TPS489.
77. Nesselhut J, Marx D, Lange H, et al. Systemic treatment with anti-PD-1 antibody nivolumab in combination with vaccine therapy in advanced pancreatic cancer. in ASCO Annual Meeting Proceedings. 2016.
78. Hardwick NR, Carroll M, Kaltcheva T, et al. P53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. Clin Cancer Res. 2014; 20:4459–4470.